2016 American Transplant Congress » Poster Session A: Kidney Desensitization

5:30pm-7:30pm

A2 Kidneys into B Recipients: Is Postoperative Anti-A1 Titer Monitoring Useful?

A. DeMers, R. Forbes, D. Moore, K. Smith, D. Shaffer.

5:30pm-7:30pm

ABO-Incompatible Living Kidney Transplantation at Multicenter Japanese Case Series: Evolution of Outcomes and Immunosuppressive Management.

K. Tanabe,¹ M. Okumi,¹ M. Furusawa,¹ K. Unagami,¹ T. Hirai,¹ H. Shirakawa,² T. Shimizu,¹ K. Omoto,³ M. Inui,¹ H. Ishida.¹

5:30pm-7:30pm

Early Hospital Readmission Among Immunologically Vulnerable Kidney Transplantation Recipients.

E. King, B. Orandi, S. Bae, X. Luo, D. Segev.

5:30pm-7:30pm

Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.

E. Woodle, M. Pando Rigal, S. Tremblay, A. Girnita.

5:30pm-7:30pm

Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.

Y. Wada, N. Fukuzawa, H. Harada.

5:30pm-7:30pm

Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.

S. Heidt, M. Witvliet, G. Haasnoot, F. Claas.

5:30pm-7:30pm

Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.

B. Orandi, E. King, X. Luo, S. Bae, B. Lonze, R. Montgomery, D. Segev.

5:30pm-7:30pm

Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.

S. Jordan, J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, M. Toyoda.

5:30pm-7:30pm

Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.

M. Matignon,¹ C. Pilon,² M. Commereuc,¹ C. Grondin,² T. Kofman,¹ P. Lang,¹ F. Canoui Poitrine,³ J. Cohen,² P. Grimbert.¹

5:30pm-7:30pm

Live Donor Kidney Transplantation of the Most Highly Sensitized Patients in the Era of Kidney Paired Donation.

A. Bingaman,¹ F. Wright,¹ M. Kapturczak,¹ L. Shen,¹ C. Murphey.²

5:30pm-7:30pm

Measuring Efficacy of Antibody Removal Therapies: Back to Titers.

A. Tambur,¹ D. Glotz,² N. Herrera,¹ E. Chatroop,¹ T. Roitberg,¹ J. Friedewald,¹ D. Gjertson.³

5:30pm-7:30pm

Successful Transplantation in ABO- and HLA-Incompatible Kidney-Transplant Patients.

L. Rostaing, N. Congy, A. Allal, L. Esposito, F. Sallusto, N. Congy, X. Doumerc, B. Debiol, N. Kamar.

5:30pm-7:30pm

Survey Results Show Strong Support for Allowing Patients Undergoing Desensitization to Keep Their Pre-Desensitization CPRA Allocation Priority.

A. Kucheryavaya,¹ R. Bray,² D. Tyan.³

5:30pm-7:30pm

The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.

J. Lee,¹ J. Park,² J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ K. Huh,¹ B. Kim,³ M. Kim,¹ S. Kim,¹ S. Ahn,² Y. Kim.¹

5:30pm-7:30pm

Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).

A. Nejad, A. Vo, J. Choi, S. Jordan.

5:30pm-7:30pm

Zero and One Mismathing for HLA DR10,14,16 Produces Increased Kidney Graft Survival.

J. Cicciarelli,^1,2 Y. Cho,² M. Altrich,¹ N. Kasahara,^1,3 N. Lemp.¹